mTOR activity has also been found to have a 24-h rhythmic pattern in cultured breast cancer cells and the efficacy of in vitro everolimus, an mTOR inhibitor, varied depending on the timing of the dose [195]. The gene discussed is MTOR; the disease is breast cancer.